Datafin

Data-driven stock analysis platform for global investors.

Sitemap
HomeScreenerValuationSector Analysis
Resources
LibraryDatafin GuideMetric MethodologyValuation MethodologiesFAQPricingWho Is Datafin?Communication
Legal
Privacy PolicyTerms of UseCookie PolicyKVKK NoticeRefund Policy
Data Sources

Financial data sourced from official regulatory filings and verified market data providers. Metrics calculated using GAAP/IFRS standards.

Disclaimer

The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

Investment decisions involve risk. Verify data independently and consult a licensed advisor when needed.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved.

Last updated: April 2026

ANN PEER ANALYSIS

Ansell Ltd — metric-by-metric comparison with peers and the industry median

ANNAnsell Ltd

🇦🇺 Australia · AU · Healthcare · Medical Instruments & Supplies

Value itDuel
PriceFinancialsPeers

Overall Profile & Returns

· Medical Instruments & Supplies

Position Within Industry

0 = weak quartile, 100 = strong quartile
ValuationProfitabilityGrowthFinancial HealthDividend
ANNIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year
Split-adjusted
ANN+6.2%XRAY-27.7%LMAT+23.8%PLSE+90.6%ATRC+1.3%STAA+58.3%
Year-to-Date (YTD)
ANN-6.2%XRAY+1.9%LMAT+27.5%PLSE+112.7%ATRC-19.6%STAA+20.4%
1-Year
Split-adjusted
ANN+6.2%FPH-2.4%RMD-20.8%
Year-to-Date (YTD)
ANN-6.2%FPH+0.3%RMD-14.7%

Key Metric Comparison

P/E

Lower is better
ANN24.16XRAY—LMAT37.97PLSE—ATRC—STAA—Median 34.91

ROE

Higher is better
ANN7.2%XRAY-37.7%LMAT16.5%PLSE-80.7%ATRC-1.0%STAA-6.0%Median 2.3%

Net Margin

Higher is better
ANN6.7%XRAY-17.1%LMAT24.3%PLSE-9,929.0%ATRC-0.8%STAA-7.2%Median 3.9%

Revenue Growth

Higher is better
ANN11.4%XRAY-1.0%LMAT13.3%PLSE-69.9%ATRC15.0%STAA4.0%Median 6.4%

P/E

Lower is better
ANN24.16FPH41.27RMD20.35Median 34.91

ROE

Higher is better
ANN7.2%FPH23.3%RMD25.2%Median 2.3%

Net Margin

Higher is better
ANN6.7%FPH20.0%RMD27.4%Median 3.9%

Revenue Growth

Higher is better
ANN11.4%FPH4.8%RMD10.5%Median 6.4%

All Metrics

Valuation
MetricANNXRAYLMATPLSEATRCSTAAInd. Median
P/E24.16●—37.97———34.91
P/B1.66●1.775.8329.863.174.012.95
EV/EBITDA12.52●—22.76—60.24—14.72
P/S1.580.63●9.252,636.182.824.872.79
Financial Health
MetricANNXRAYLMATPLSEATRCSTAAInd. Median
Current Ratio2.361.5314.32●7.264.295.122.40
Debt/Equity46.2%176.9%46.7%10.8%15.2%10.6%●34.8%
NetDebt/EBITDA2.10-16.86●-1.840.83-2.8830.831.44
Profitability
MetricANNXRAYLMATPLSEATRCSTAAInd. Median
Net Margin6.7%-17.1%24.3%●-9,929.0%-0.8%-7.2%3.9%
ROE7.2%-37.7%16.5%●-80.7%-1.0%-6.0%2.3%
ROA4.2%-11.1%10.5%●-69.4%-0.7%-4.6%1.5%
EBITDA Margin15.2%-3.5%37.6%●-9,866.7%4.5%-1.4%13.8%
Growth + Dividend
MetricANNXRAYLMATPLSEATRCSTAAInd. Median
Rev. Growth11.4%-1.0%13.3%-69.9%15.0%●4.0%6.4%
NI Growth23.8%—38.2%●———14.0%
Div. Yield1.7%4.3%●0.9%—0.0%—1.7%
Payout53.2%-20.4%30.9%—0.0%—22.4%
Valuation
MetricANNFPHRMDInd. Median
P/E24.1641.2720.35●34.91
P/B1.66●9.084.732.95
EV/EBITDA12.52●23.2913.8314.72
P/S1.58●8.275.562.79
Financial Health
MetricANNFPHRMDInd. Median
Current Ratio2.362.313.01●2.40
Debt/Equity46.2%6.9%●13.0%34.8%
NetDebt/EBITDA2.10-0.39●-0.381.44
Profitability
MetricANNFPHRMDInd. Median
Net Margin6.7%20.0%27.4%●3.9%
ROE7.2%23.3%25.2%●2.3%
ROA4.2%17.3%18.6%●1.5%
EBITDA Margin15.2%34.9%39.1%●13.8%
Growth + Dividend
MetricANNFPHRMDInd. Median
Rev. Growth11.4%●4.8%10.5%6.4%
NI Growth23.8%●-11.6%15.9%14.0%
Div. Yield1.7%1.6%8.0%●1.7%
Payout53.2%53.9%22.4%22.4%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on ANN

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 3, 26. This content is for informational purposes only and is not investment advice.